New drug combo targets Hard-to-Treat cancers in early trial

NCT ID NCT06115642

ENROLLING_BY_INVITATION Disease control Sponsor: Shanghai Henlius Biotech Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called HLX43, an antibody-drug conjugate that targets PD-L1, in people with advanced or metastatic solid tumors that have not responded to standard treatments. Participants also receive another immunotherapy drug, serplulimab (HLX10). The main goals are to check safety, find the right dose, and see if tumors shrink. About 367 people will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HLX43 (anti-PD-L1 antibody-drug conjugate) and HLX10 (serplulimab)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is an early Phase 1 trial, so safety and effectiveness are not yet proven. The drug may cause serious side effects or not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC MALIGNANT SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm non-small cell lung carcinoma thymic carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED/METASTATIC MALIGNANT SOLID TUMORS

Contacts and locations

Locations

Cancer Hospital, Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China
Georgetown University

Washington D.C., District of Columbia, 20057, United States
Kindai University Hospital

Sayama, Osaka, 589-8511, Japan
MD Anderson Medical Center

Houston, Texas, 77030, United States
National Cancer Center Hospital

Tokyo, 104-0045, Japan
Okayama University Hospital

Okayama, 700-8558, Japan
Sendai Kousei Hospital

Sendai, Miyagi, 980-0873, Japan
Shizuoka Cancer Center

Shizuoka, 411-8777, Japan
Stanford University

Stanford, California, 94305, United States
Xiangya Hospital Central South University

Changsha, Hu'nan, 410008, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.